Table 2 Characterization of therapy-related myeloid neoplasms
Latency (months) | 35 (3–118) |
|---|---|
Patients with persistent cytopenia after FCR (n=10) (months) | 23 (3–43) |
Patients recovered CBC after FCR and later developed cytopenia (n=18) (months) | 42 (24–118) |
Cytopenia (at diagnosis of t-MN) | |
Anemia | n=18 |
Hemoglobin (g/dl) | Median/range 10 (6.6–15.7) |
Thrombocytopenia | n=19 |
Platelets ( × 109/l) | Median/range 45.5 (7–388) |
Neutropenia | n=16 |
Absolute neutrophil count (ANC) ( × 109/l) | Median/range 1.1(0.2–5.9) |
Bicytopenia | n=10 |
Pancytopenia | n=9 |
Bone marrow | |
Cellularity (%) | 40 (20–90) |
Dysplasia | |
Trilineage dysplasia | n=18 |
Bilineage dysplasia | n=3 |
Single lineage dysplasia | n=4 |
Ring sideroblasts | n=12 (2–46%) and ≥15% in 8 cases |
CLL/SLL in bone marrow | |
Negative | n=17 |
≤10% | n=6 |
>10% | n=5 |
t-MN subtypes by WHO criteria | |
t-AML | n=5 |
t-MDS | n=23 |
RAEB-1 | n=5 |
RAEB-2 | n=3 |
RCMD | n=11 |
RARS | n=2 |
MDS-U | n=2 |
Cytogenetics | |
Diploid | n=1 |
Abnormal karyotype | n=26 |
−5/del(5q) and/or −7/del(7q) | n=18 |
Complex karyotype | n=2 |
Trisomy 8 | n=3 |
−20/del(20q) | n=2 |
Disease-specific survival (months) | Median=7 (1–22) |
